Related coverage linked through entity extraction aliases.
Aug 23, 2026
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
Jun 30, 2026
Recent studies show that resistance training lowers cardiovascular disease risk in women, muscular strength is tied to lower mortality in older women, and both weekend warrior and regular exercise patterns reduce mortality in patients with hypertension.
Jun 08, 2026
UKCA approval was granted for the LVOne stroke blood test, piloting with London Ambulance Service. A phase 2 trial showed LT 3001 is safe up to 24 hours post-stroke; 'leaky core' imaging links barrier disruption to worse outcomes.
Apr 20, 2026
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
Mar 07, 2026
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
Mar 05, 2026
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
